NTRK1 and gastrointestinal stromal tumor: Moreover, sunitinib, a multitargeted receptor tyrosine kinase (RTK) inhibitor [58], which was approved as an anticancer agent in gastrointestinal stromal tumor patients, was shown to inhibit cancer cell growth expressing RTKs [59,60].